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ORIGINAL ARTICLE
Background/Aims: Although high-flux (HF) dialyzers with enhanced membrane permeability are widely used in
current hemodialysis (HD) practice, urea kinetic modeling is still being applied to indicate the adequacy of both
low-flux (LF) and HF HD. In comparison with urea (molecular weight, 60 Da) and β2-microglobulin (β2MG,  12
kDa), cystatin C (CyC, 13 kDa) is a larger molecule that has attractive features as a marker for assessing solute
clearance. We postulated that CyC might be an alternative for indicating the clearance of middle molecules
(MMs), especially with HF HD.
Methods: Eighty-nine patients were divided into LF and HF groups. Using single pool urea kinetic modeling, the
urea reduction ratio (URR) and equilibrated Kt/Vurea (eKt/Vurea) were calculated. The serum CyC concentrations
were measured using particle-enhanced immunonephelometry. As indices of the middle molecular clearance, the
reduction ratios of β2MG and CyC were calculated. 
Results: The β2MG reduction ratio (β2MGRR) and CyC reduction ratio (CyCRR) were higher in the HF group
compared to the LF group. However, the URR and eKt/Vurea did not differ between the two groups. The CyCRR
was significantly correlated with the eKt/Vurea and β2MGRR (r = 0.47 and 0.69, respectively, both p < 0.0001). 
Conclusions: Compared to the LF dialyzer, the HF dialyzer removed CyC and β2MG more efficiently. Unlike the
β2MGRR, the CyCRR was correlated with the eKt/Vurea and β2MGRR. This study suggests a role for the CyCRR
as an alternative indicator of the removal of MMs. (Korean J Intern Med 2010;25:77-81)
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INTRODUCTION
The uremic syndrome is attributable to the progressive
retention of a large number of compounds, which are
called uremic retention solutes or uremic toxins, when
they interact negatively with physiologic function. They
include not only small plasma solutes, but also protein-
bound solutes and middle molecules (MMs) [1]. Their
retention may lead to dialysis morbidity and mortality,
which are poorly resolved with conventional hemodialysis
(HD).
Since the beginning of the 1980s, urea kinetic modeling
has been applied to quantify the removal of small solutes
by conventional HD. In current practice, high-flux (HF)
dialyzers may allow more efficient removal of larger
molecules, which is expected to reduce the risk of HD-
related morbidity and mortality substantially. Conversely,
no consensus exists concerning the best dialysis dose
index and method for calculating it [2,3].
Of the MMs, cystatin C (CyC, molecular weight [MW],
13 kDa) is freely filtered at the level of the glomerulus and
virtually all is reabsorbed and metabolized by proximal
tubular cells [4-7]. Due to its molecular characteristics,
numerous studies have shown that CyC is the mostpromising endogenous marker of the glomerular filtration
rate [8]. In addition, several studies have suggested that
CyC is useful as a marker of HD toxin removal, since the
plasma CyC has attractive features as a representative MM
[9,10].
For these reasons, we hypothesized that the CyC
reduction ratio (CyCRR) might reflect the removal of
MMs and could be applied to the dialysis dose index in
HD, and we designed this single-center, case-control
study to examine our hypotheses. 
METHODS
Patients
All of the patients underwent maintenance HD at
Hanyang University Hospital three times per week.
Previously, all 89 patients had chosen low-flux (LF) HD as
the dialysis modality. The dialysis modality was chosen
according to patient preference, and the dialyzers used
were F6HPS for LF and F60S for HF (Fresenius Medical
Care, Bad Homburg, Germany). We assumed that no
residual renal function was preserved in any patient.
Patients were excluded if they were medically unstable,
younger than 18 years of age, or mentally disabled. 
Measurements
All blood samples were taken before and after the second
HD session of the week, according to the guidelines for
HD adequacy [11]. Blood samples were collected in tubes
without additional anticoagulant and allowed to stand at
room temperature for 30 to 60 minutes. Then, the samples
were centrifuged to collect serum, which was stored at -
70˚C until assayed. Urea nitrogen was measured using a
Hitachi 7600 series automatic biochemical analyzer
(Hitachi High-Technologies, Tokyo, Japan). Serum β2-
microglobulin (β2MG, MW, 12 kDa) concentrations were
measured using a chemiluminescent enzyme immunoassay
(DPC IMMUNLITE 2000, Diagnostic Products, Los
Angeles, CA, USA). CyC was assayed using particle-
enhanced immunonephelometry (BN II nephelometer,
Dade Behring, Reuil Malmaison, France). All other mea-
surements were made using routine laboratory methods. 
We calculated the reduction ratios of solutes for urea,
β2MG, and CyC during the treatment. The single-pool
urea Kt/V (spKt/Vurea) values were calculated using the
second-generation natural logarithmic formula described
by Daugirdas [12], and we transformed the spKt/Vurea to
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Table 1. Demographic characteristics
Low-flux hemodialysis High-flux hemodialysis p value
(n = 37) (n = 52)
Age, yr 56.1 ± 12.2 54.0 ± 12.4 NS
Male gender 17 (46.0) 25 (48.1) NS
Diabetes mellitus 14 (37.8) 15 (28.9) NS
Duration of hemodialysis, mon 71.6 ± 79.9 112.7 ± 188.6 NS
Body mass index, kg/m
2 20.9 ± 3.0 20.7 ± 2.8 NS
Hemoglobin, g/dL 9.7 ± 1.5 9.8 ± 1.1 NS
C-reactive protein 0.38 ± 0.44 0.17 ± 0.24 0.0039
Values are presented as mean ± SD for continuous variables and number (%) for nominal variables.
NS, not significant. 
Table 2. Clearance according to dialyzer
Low-flux hemodialysis High-flux hemodialysis p  value
Urea reduction ratio, % 67.8 ± 13.0 70.3 ± 6.7 NS
eKt/Vurea 1.19 ± 0.32 1.29 ± 0.23 NS
β2MG reduction ratio, % 7.0 ± 25.0 42.5 ± 14.9 < 0.0001
Kt/Vβ2MG 0.24 ± 0.38 0.84 ± 0.29 < 0.0001
CyC reduction ratio, % 11.5 ± 16.2 42.4 ± 6.3 < 0.0001
Values are presented as the mean ± SD.
eKt/Vurea, equilibrated Kt/Vurea; β2MG, β2-microglobulin; CyC, cystatin C; NS, not significant. the equilibrated Kt/Vurea (eKt/Vurea) [13].
The clearance of β2MG (Kβ2MG) was determined using
the formula described by Cheung et al. [14] and then the
Kt/Vβ2MG was calculated by multiplying the Kβ2MG by the
treatment time and dividing the result by the post-dialysis
volume.
Statistical analysis
Baseline characteristics are presented as the mean ± SD
or as the proportions of patients in the groups. The
Shapiro-Wilk test was used to test for normality. Continuous
variables were compared using the Mann-Whitney U test.
The chi-square test with Fisher’s exact test was applied to
evaluate associations between nominal variables. The
Spearman correlation coefficient was used to study
correlations between variables. All p values were analyzed
using two-sided tests, and pvalues < 0.05 were considered
statistically significant. All analyses were performed with
SAS version 9.1 (SAS Institute, Cary, NC, USA).
RESULTS
Eighty-nine patients were included and divided into LF
(n = 37) and HF (n = 52) groups. Dialysis was performed
for 4.0 ± 0.2 hr/session with blood flow rates of 237 ± 23
mL/min and dialysate flow rates of 500 mL/min using
bicarbonate dialysate. The dialysis machine, water
treatment circuit, and tank were sterilized regularly.
No differences existed between the two groups with
respect to the demographic characteristics and the cause
of end-stage renal disease (Table 1). The C-reactive protein
was higher in the LF HD group (p = 0.0039), but was not
correlated with the indices of solute removal in this study
(data not shown). The etiology of renal failure in the
patients included diabetes mellitus (n = 29, 32.6%),
hypertension (n = 18, 20.2%), chronic glomerulonephritis
(n = 12, 13.5%), and shrunken kidneys of unknown etiology
(n = 23, 25.8%). 
The eKt/Vurea in the LF and HF HD groups was 1.19 ±
0.32 and 1.29 ± 0.23, respectively. No differences were
observed in the urea reduction ratio (URR) and eKt/Vurea
between the two groups (Table 2). However, β2MG and
CyC were removed more efficiently by the HF dialyzer (p
< 0.0001).
When all patients were considered, the CyCRR was
strongly correlated with the β2MG reduction ratio
(β2MGRR) and Kt/Vβ2MG and weakly correlated with the
URR and eKt/Vurea (Table 3). The pre-dialysis CyC and
β2MG levels, and their reduction ratios were not correlated
with the albumin, normalized protein catabolic rate, or C-
reactive protein (data not shown).
DISCUSSION
We assessed the performance of the CyCRR as repre-
sentative of the clearance of MMs. As in previous reports
[14,15], no difference existed between the two groups in
terms of the URR and eKt/Vurea. In addition, the more
efficient removal of β2MG in the HF HD group concurred
with a past study [14]. However, we found that the CyCRR
had a prominent relationship with the β2MGRR and
Kt/Vβ2MG in HD.
Most of the small water-soluble uremic retention
compounds and MMs that have been shown to exert
biologic action have an intradialytic kinetic behavior that
is indisputably different from that of urea [16], and their
retention is poorly resolved with conventional HD.
Therefore, many past studies have emphasized that
the removal of small water-soluble uremic retention
compounds and MMs using a HF dialyzer may ensure
excellent dialysis quality, influence the clinical outcomes
of patients in several areas, and reduce the acute and long-
term HD-related complications [1,17-20]. These may be
particularly important in patients with no residual renal
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Table 3. Correlation coefficient between clearance
Urea reduction ratio eKt/Vurea β2MG reduction ratio Kt/Vβ2MG
β2MG reduction ratio 0.2508a 0.3375b
Kt/Vβ2MG 0.2227 0.2904
CyC reduction ratio 0.3962b 0.4692b 0.6920b 0.6861b
eKt/Vurea, equilibrated Kt/Vurea; β2MG, β2-microglobulin; CyC, cystatin C.
ap < 0.05.
bp < 0.01.function, who depend completely on dialysis efficiency.
Assessing dialysis adequacy using several molecules
simultaneously is suitable to reflect small solute and MM
clearance [21].
β2MG had been accepted as representative of MMs and
is widely recognized as a key component in the development
of dialysis-associated amyloidosis [22]. Several studies
demonstrated that the use of a HF dialyzer might improve
the clearance of β2MG and decrease pre-dialysis plasma
levels [23,24]. They expected that HD with a HF dialyzer
could reduce the development of amyloidosis and improve
patient quality of life. Given the fluctuating β2MG pro-
duction rate, nonrenal route of elimination, other factors
influencing its bloodstream delivery, and intercompartmental
transport, β2MG removal is recognized as not being a
good indicator [25,26].
After exploring the interrelationship of low-molecular-
weight proteins with the glomerular filtration rate, an
increasing serum CyC level was found to be related to
decreasing renal function and to be associated with some
cerebral amyloid angiopathies, tumor progression, and
inflammatory processes [27-30]. In addition, some
attractive features as a representative MM made us assess
the performance of CyC during HD: because CyC should
be distributed strictly in extracellular fluid, various kinetic
models are not required to describe its kinetics during
HD; its production rate is relatively constant or minimally
variable; CyC is a free-circulating, unbounded form, and
its elimination from the circulation is almost entirely
through glomerular filtration; and CyC may be a prognostic
biomarker of the risk of death and cardiovascular disease
[31,32].
Starting from the hypothesis that the clearance of CyC is
representative of the removal of MMs and its reduction
ratio is a useful marker of toxin removal in HD, we
performed this study to compare the CyCRR with the
most widely used methods for measuring HD adequacy.
Since CyC has several merits as a representative MM - it is
similar to β2MG in molecular weight and clearance during
HD, and its reduction ratio has some relationship with the
URR and eKt/Vurea - the CyCRR should be useful as an
alternative to the β2MGRR and Kt/Vβ2MG for estimating
the dialysis clearance of MMs. However, further studies
with larger sample sizes should be performed to draw a
firm conclusion as to whether the CyCRR is useful
indicator of the clearance of MMs.
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